2-Amino-6-methylheptane hydrochloride

We are 2-Amino-6-methylheptane hydrochloride CAS:5984-59-8 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests


Product Name: 2-Amino-6-methylheptane hydrochloride
Synonym: (1,5-dimethylhexyl)ammonium chloride; 2-Isooctylamine hydrochloride; DMHA
Cas No.: 5984-59-8
Formula: C₈H₂₀ClN
MW: 165.70
EINECS No.:227-798-5

HS Code: 2921199090

UN No.: N.A
Hazard class: Non-dangerous goods
 
Specification

Items of Analysis	Standard of Analysis	Test Results
Appearance	White to off-white powder	Conform
Assay(GC)	≥98.0%	98.55%
Loss on Drying	≤1.0%	0.10%
Residue on ignition	≤1.0%	0.16%
Heavy Metals	≤10ppm	Confirm
Lead (Pb)	≤1ppm	Confirm
Arsenic (As)	≤1ppm	Confirm
Cadmium (Cd)	≤1ppm	Confirm
Mercury (Hg)	≤0.1ppm	Confirm
Total plate count	≤1000cfu/g	Confirm
Yeast and mold	≤100cfu/g	Confirm
Enterobacteriaceae	＜100 cfu/g	Confirm
E.Coli	Absent/10g	Negative
CPS	Absent/10g	Negative
Salmonella	Negative	Negative
Listeria	Negative	Negative
Conclusion	Conforms to Factory Standard

 
 
Application
Health care product additive.
 
Packaging
25 kg/barrel, can also be packaged according to customer requirements. 
 
Storage
Store in a cool, ventilated warehouse. 
Keep away from fire and heat. 
The temperature should not exceed 37 °C. 




Related News: “CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.2-Ethylhexyl 4-(Dimethylamino)benzoate CAS:21245-02-3 “CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.100306-34-1 “CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.D-Arginine Monohydrochloride CAS:627-75-8 CMO services mainly involve four stages: pre-clinical research, clinical trials, sales of patented drugs after listing, and sales of original drug products after patents expire. Its advantages are: lower cost, guaranteed quality, good capacity flexibility, and favorable process Promotion.CMO services mainly involve four stages: pre-clinical research, clinical trials, sales of patented drugs after listing, and sales of original drug products after patents expire. Its advantages are: lower cost, guaranteed quality, good capacity flexibility, and favorable process Promotion.